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Abstract
Background: Obesity and inactivity are associated with increased risk of cancer-related and overall mortality in breast cancer,
but there are few data in metastatic disease. Methods: Cancer and Leukemia Group B 40502 was a randomized trial of firstline taxane-based chemotherapy for patients with metastatic breast cancer. Height and weight were collected at enrollment.
After 299 patients enrolled, the study was amended to assess recreational physical activity (PA) at enrollment using the
Nurses’ Health Study Exercise Questionnaire. Associations with progression-free survival (PFS) and overall survival (OS) were
evaluated using stratified Cox modeling (strata included hormone receptor status, prior taxane, bevacizumab use, and treatment arm). All statistical tests were 2-sided. Results: A total of 799 patients were enrolled, and at the time of data lock,
median follow-up was 60 months. At enrollment, median age was 56.7 years, 73.1% of participants had hormone receptor–
positive cancers, 42.6% had obesity, and 47.6% engaged in less than 3 metabolic equivalents of task (MET) hours of PA per
week (<1 hour of moderate PA). Neither baseline body mass index nor PA was statistically significantly associated with PFS or
OS, although there was a marginally statistically significant increase in PFS (hazard ratio ¼ 0.83, 95% confidence interval ¼
0.79 to 1.02; P ¼ .08) and OS (hazard ratio ¼ 0.81, 95% confidence interval ¼ 0.65 to 1.02; P ¼ .07) in patients who reported PA
greater than 9 MET hours per week vs 0-9 MET hours per week. Conclusions: In a trial of first-line chemotherapy for metastatic breast cancer, rates of obesity and inactivity were high. There was no statistically significant relationship between body
mass index and outcomes. More information is needed regarding the relationship between PA and outcomes.

Obesity is a well-established risk factor for poor prognosis in
women with early stage breast cancer (1-4). A meta-analysis
conducted by the World Cancer Research Fund of 82 reports
evaluating the relationship between body mass index (BMI) and
mortality in women with stage I-III breast cancer reported a 35%
increase in breast cancer–related mortality and a 41% increase
in overall mortality in women with obesity at the time of breast
cancer diagnosis as compared with women who were of normal
weight (4). The relationship between obesity and poor outcomes
was seen in both pre- and postmenopausal women. Other
meta-analyses have demonstrated that obesity is associated

with increased risk of cancer recurrence and mortality in both
hormone receptor–positive and hormone receptor–negative
breast cancers (5,6).
Although data are more limited, physical activity (PA) is also
increasingly being linked to breast cancer outcomes. A metaanalysis of 13 cohort studies evaluating the relationship between PA after breast cancer diagnosis and mortality in individuals with stage I-III breast cancer demonstrated that breast
cancer survivors who engaged higher levels of PA after cancer
diagnosis had a 37% lower risk of breast cancer–specific mortality (hazard ratio [HR] ¼ 0.63, 95% confidence interval [CI] ¼ 0.50
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Methods
Study Cohort
The patient cohort for this study was derived from the study
population of CALGB 40502 (NCT00785291) (13,14), a phase III
randomized trial comparing paclitaxel with nanoparticle albumen bound-(nab-)paclitaxel or ixabepilone þ/- bevacizumab as
first-line chemotherapy for locally recurrent or MBC.
Participants were randomly assigned 1:1:1 to paclitaxel (90 mg/
m2), nab-paclitaxel (150 mg/m2), or ixabepilone (16 mg/m2). All
chemotherapy was administered 3 weeks on, 1 week off.
Participants were also treated with bevacizumab (10 mg/kg every 2 weeks). In March 2011, the protocol was amended to make
bevacizumab use optional; nevertheless, 97% of participants received the agent. Eligibility criteria included the presence of
metastatic or locally recurrent breast cancer; no prior chemotherapy for advanced disease; being at least 12 months from adjuvant taxane; and having measurable disease, adequate organ
function and Eastern Cooperative Oncology Group performance
status (ECOG PS) of 1 or less, and no grade 2 or greater peripheral
neuropathy (13).
The study was open to enrollment between November 2008
and November 2011. The CALGB, ECOG, Southwest Oncology
Group, and North Central Cancer Treatment Group (NCCTG)
participated in the study (CALGB and NCCTG are now part of
the Alliance for Clinical Trials in Oncology). All participants
signed an institutional review board–approved, protocolspecific informed consent document meeting all federal and institutional regulatory requirements. Study results have been
published previously (13).

Measures
Height and weight were collected at the time of participant enrollment. BMI was calculated according to the formula: BMI ¼
weight (kg)/height (m) (2). BMI categories were defined according to the World Health Organization as underweight (<18.5 kg/
m2), normal weight (18.5-24.9 kg/m2), overweight (25-29.9 kg/
m2), and obese (30 kg/m2).
An amendment was added to the protocol after 299 participants had been enrolled requiring that participants complete
the Nurses’ Health Study Exercise Questionnaire (NHSEQ) at the
time of study enrollment. The NHSEQ captures the frequency,

type, and duration of recreational PA. Metabolic equivalents of
task (MET) hours of weekly recreational PA were calculated using the Ainsworth Physical Activity Compendium (15).

Statistical Analysis
The analysis cohort is comprised of eligible participants who
were classified as normal weight, overweight, or obese at the
time of study entry using the World Health Organization classification scheme. Given the small number of participants classified as underweight, these participants (n ¼ 9) were omitted
from analyses. PA was categorized as 0-9 MET hours per week
and more than 9 MET hours per week, based on guidelines’
recommendation of 150-180 minutes of moderate-intensity PA
per week, which is consistent with 9 MET hours per week of
PA (16,17).
Chi-square tests were used to assess whether patient or disease characteristics at registration differed with respect to BMI
or PA category. PFS was defined as the time from date of randomization until date of first progression or death from any
cause. Patients without documentation of a disease event were
censored at the date of their last disease evaluation. OS was defined as the time from date of randomization until death due to
any cause. Stratified Cox modeling with the stratification factors treatment assignment, hormone receptor status, prior taxane, and use of bevacizumab were used to assess whether PFS
or OS differed with respect to BMI or PA in the analysis cohort.
For the subgroup of patients with hormone receptor–positive
breast cancer and the group of patients with hormone receptor–
negative breast cancer, stratified log-rank tests with treatment
assignment as the stratification factor were used to assess
whether PFS or OS differed with respect to BMI or PA. Adverse
event data were collected using Common Terminology Criteria
for Adverse Events v4.0 criteria. Chi-square tests were used to
assess whether proportion of severe adverse events (grade 3 or
higher regardless of attribution) differed by BMI and PA within
treatment arms. Analyses were performed using SAS software
(version 9.4; SAS Institute Inc) on a database locked on May 3,
2017.
Data collection and statistical analyses were conducted by
the Alliance Statistics and Data Center. Data quality was ensured by review of data by the Alliance Statistics and Data
Center and by the study chairperson following Alliance policies.

Results
Participant Characteristics
Overall, 799 individuals were enrolled in CALGB 40502, 783 of
whom initiated protocol treatment (see Consort Diagram,
Figure 1). Of these 783 participants, 9 were found to be underweight and omitted from analyses. Thus, the analytic cohort for
this report is comprised of s the 774 eligible participants who
initiated protocol treatment and were classified as normal
weight, overweight, or obese at the time of study entry. Baseline
characteristics are presented in Table 1. Median age was
56.7 years, 73.1% of patients had hormone receptor–positive
cancers, 43.8% had received a taxane in the adjuvant setting,
57.5% were diagnosed with MBC at least 2 years after initial diagnosis, and 61.1% had an ECOG score of 0.
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to 0.78; P < .01) compared with less active breast cancer
survivors (7).
Less is known regarding the relationships between obesity
and inactivity and outcomes in individuals with metastatic
breast cancer (MBC). A few studies have evaluated the relationship between BMI and progression-free survival (PFS) or overall
survival (OS) in individuals with MBC (8–12), but most reports
have focused specifically on individuals with HER2-positive
breast cancer or with brain metastases. Results of these studies
have been mixed. There is almost no information about PA patterns among individuals with MBC or about the relationship between PA and cancer outcomes in this population.
We evaluated the relationships between BMI and PA patterns with PFS and OS in patients participating in Cancer and
Leukemia Group B (CALGB) 40502 (13), a randomized trial comparing the efficacy of 3 chemotherapy regimens, in combination
with bevacizumab, as first-line therapy for patients with MBC or
locally recurrent, unresectable breast cancer.
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Assessed for eligibility (n = 799)

Randomized (n = 799)

Allocated to nab-paclitaxel
intervention (n = 271)
i Received intervention (n = 267)
i Did not receive intervention (n = 4)

BMI analysis (n = 273)
i Excluded underweight patients
(BMI <18.5 kg/m2) (n = 2)

BMI analysis (n = 263)
i Excluded underweight patients
(BMI <18.5 kg/m2) (n = 4)

BMI analysis (n = 238)
i Excluded underweight patients
(BMI <18.5 kg/m2) (n = 3)

Physical Activity Data
Analyzed (n = 176)
i Excluded from analysis (no
baseline physical activity data
available) (n = 97)

Physical Activity Data
Analyzed (n = 170)
i Excluded from analysis (no
baseline physical activity data
available) (n = 93)

Physical Activity Data
Analyzed (n = 146)
i Excluded from analysis (no
baseline physical activity data
available) (n = 92)

Allocated to ixabepilone
intervention (n = 245)
i Received intervention (n = 241)
i Did not receive intervention (n = 4)

Figure 1. CONSORT diagram. BMI ¼ body mass index.

BMI and Tumor and Host Characteristics
Distribution of BMI categories was similar across treatment groups
(data not shown). Median BMI was 28.6 kg/m2 (interquartile range ¼
24.7-33.1 kg/m2). Overall, 26.1% of participants were classified as normal weight, 31.2% overweight, and 42.6% obese. BMI was statistically significantly associated with race and performance status.
Individuals with obesity were more likely to be Black (18.5% vs
10.9% [normal weight] and 9.5% [overweight]; P ¼ .02) and less likely
to have had a disease-free interval of more than 2 years between initial diagnosis and diagnosis of metastatic disease compared with
normal weight or overweight individuals (50.9% vs 60.4% [normal
weight] and 64.0% [overweight]; P ¼ .04). No statistically significant
relationship was found between BMI and tumor hormone receptor
status or the presence of visceral metastases.

Baseline BMI and Cancer Outcomes
At a median follow-up of 60 months, there were 725 PFS events and
622 deaths among the 774 study participants. No statistically significant difference in PFS was found between those patients classified
as obese (HR ¼ 1.01, 95% CI ¼ 0.83 to 1.22; P ¼ .93) or overweight (HR
¼ 1.03, 95% CI ¼ 0.84 to 1.26; P ¼ .77) relative to those classified as
having normal weight. Similarly, no statistically significant

difference in OS was found between those patients classified as
obese (HR ¼ 1.03, 95% CI ¼ 0.84 to 1.26; P ¼ .79) or overweight (HR ¼
1.14, 95% CI ¼ 0.92 to 1.41; P ¼ .24) relative to those classified as having normal weight. Median PFS and OS were 9.8 months (95% CI ¼
9.0 to 11.1) and 26.8 months (95% CI ¼ 22.1 to 32.3) in patients classified as normal weight, 9.1 months (95% CI ¼ 7.6 to 10.3) and
22.0 months (95% CI ¼ 19.9 to 25.2) in patients classified as overweight, and 8.7 months (95% CI ¼ 7.8 to 9.7) and 25.8 months (95% CI
¼ 23.5 to 29.5) in patients classified as obese (Figure 2). Subset analyses showed that these results were similar in the subsets of participants with hormone receptor–positive and hormone receptor–
negative tumors (data not shown).

Physical Activity and Tumor and Host Characteristics
Of the 774 patients included in the BMI analyses, 492 enrolled
after the activation of the protocol amendment instituting the
collection of PA data. Patient and tumor characteristics of these
participants are included in Table 2. No statistically significant
differences were found with respect to availability of PA data,
and there were no differences in PA levels across treatment
groups (data not shown). Participants engaged in a median of
3.3 MET hours per week of PA (about 1 hour of moderate intensity activity per week; interquartile range ¼ 0.7-12.7 MET hours
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Allocated to paclitaxel intervention
(n = 283)
i Received intervention (n = 275)
i Did not receive intervention (n = 8)
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Table 1. Patient characteristics by baseline body mass index (n ¼ 774)
Body mass index

Characteristic

Overweight
(n ¼ 242)

Obese
(n ¼ 330)

57 (23-85)

56 (34-86)

56 (28-83)

52 (25.7)
127 (62.9)
23 (11.4)

61 (25.2)
154 (63.6)
27 (11.2)

80 (24.2)
220 (66.7)
30 (9.1)

2 (1.0)
200 (99.0)

3 (1.2)
239 (98.8)

6 (1.8)
324 (98.2)

167 (82.7)
22 (10.9)
13 (6.4)

206 (85.1)
23 (9.5)
13 (5.4)

251 (76.1)
61 (18.5)
18 (5.5)

78 (38.6)
124 (61.4)

104 (43.0)
138 (57.0)

157 (47.6)
173 (52.4)

159 (79.1)
42 (20.9)
1

193 (80.4)
47 (19.6)
2

262 (79.4)
68 (20.6)
0

18 (8.9)
44 (21.8)
18 (8.9)
122 (60.4)

28 (11.6)
39 (16.1)
20 (8.3)
155 (64.0)

46 (13.9)
77 (23.3)
39 (11.8)
168 (50.9)

20 (11.0)
162 (89.0)
20

20 (9.1)
199 (90.9)
23

27 (8.8)
281 (91.2)
22

153 (75.7)
49 (24.3)

178 (73.6)
64 (26.4)

235 (71.2)
95 (28.8)

116 (57.7)
78 (38.8)
8

164 (68.3)
71 (29.6)
7

193 (58.5)
126 (38.2)
11

P
.76a
.86b

.80c

.02b

.12b

.93b

.04b

.70b

.51b

.04b

a

Two-sided Wilcoxon rank sum test or Kruskal-Wallis test. ECOG ¼ Eastern Cooperative Oncology Group; ER ¼ estrogen receptor; PR ¼ progesterone receptor.

b

Two-sided v2 test.

c

Two-sided Fisher exact test.

per week). Almost 70% of participants engaged in fewer than 9
MET hours per week of PA, with 47.6% of patients engaging in
fewer than 3 MET hours per week.
Baseline PA was statistically significantly associated with
performance status (Table 2). Fewer participants who engaged
in fewer than 9 MET hours per week of PA had a performance
status of 0 compared with participants who engaged in more
than 9 MET hours per week (57.2% vs 75.7%; P < .001). No statistically significant association was found between PA and race,
age, tumor hormone receptor status, duration of disease-free
interval between diagnosis and development of metastatic disease, or presence of visceral metastases.

Baseline PA and Cancer Outcomes
After 60 months of median follow-up, 467 PFS events and 392
deaths had occurred in the 492 participants for whom baseline

PA was available. There was a marginally statistically significant increase in PFS (HR ¼ 0.83, 95% CI ¼ 0.79 to 1.02; P ¼ .08)
and OS (HR ¼ 0.81, 95% CI ¼ 0.65 to 1.02; P ¼ .07) in participants
who completed more than 9 MET hours per week of PA relative
to those who completed 0-9 MET hours per week of PA
(Figure 3). Median PFS and OS were 8.0 months (95% CI ¼ 7.4 to
9.2) and 23.6 months (95% CI ¼ 20.3 to 26.5), respectively, in
participants completing 0-9 MET hours per week of PA and
9.8 months (95% CI ¼ 8.8 to 12.0) and 27.8 months (95% CI ¼ 21.5
to 35.6) in participants completing more than 9 MET hours per
week.
Among the 366 participants with hormone receptor–positive
cancers, there was a trend between PA and longer PFS (HR ¼
0.83, 95% CI ¼ 0.79 to 1.02; P ¼ .16) and OS (HR ¼ 0.81, 95% CI ¼
0.65 to 1.02; P ¼ .18) for those who completed more than 9 MET
hours per week of PA relative to those who completed 0-9 MET
hours per week of PA (Figure 4). Median PFS and OS were
9.5 months (95% CI ¼ 8.0 to 10.9) and 27.1 months (95% CI ¼ 24.0
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Median age (range), y
Age, No. (%), y
20-49
50-69
70 to 80
Sex, No. (%)
Male
Female
Race, No. (%)
White
Black
Other/unknown
Taxane as adjuvant therapy, No. (%)
Yes
No
Visceral metastases, No. (%)
Yes
No
Missing
Disease-free interval, No. (%)
0 (de novo)
<1 y
1 y < disease-free interval < 2 y
>2 y
Clinical stage, No. (%)
Not IV
IV
Missing
Tumor subtype, No. (%)
ER and/or PR positive
ER and PR negative
ECOG performance, No. (%)
0
1
Missing

Normal
(n ¼ 202)
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cation factors including treatment assignment, hormone receptor status, prior taxane, and use of bevacizumab.

to 32.3), respectively, in participants who completed 0-9 MET
hours per week of PA and 11.7 months (95% CI ¼ 9.9 to 13.5) and
34.0 months (95% CI ¼ 27.4 to 42.0) in participants who completed more than 9 MET hours per week of PA. Among the 126
participants with hormone receptor–negative cancers, no statistically significant association was seen between PA and PFS
(P ¼ .31) or OS (P ¼ .38). Median PFS and OS were 6.6 months (95%
CI ¼ 5.6 to 7.4) and 13.9 months (95% CI ¼ 11.4 to 18.5), respectively, in participants who completed 0-9 MET hours per week
of PA and 5.9 months (95% CI ¼ 5.5 to 8.9) and 15.6 months (95%
CI ¼ 14.1 to 22.6) in participants who completed more than 9
MET hours per week of PA.

BMI, PA, and Treatment Toxicity
Toxicity information by treatment arm was available for 792
patients with baseline BMI data and 495 patients with baseline
PA data (Table 3). The majority of patients experienced at least
one grade 3 or greater hematologic or nonhematologic toxicity.
There was no statistically significant difference by BMI in the
proportion of patients who reported a grade 3 or higher nonhematologic toxicity in participants treated with paclitaxel
(P ¼ .99) or nab-paclitaxel (P ¼ .70). However, among participants
treated with ixabepilone, individuals who were overweight or
had obesity were more likely to experience a grade 3 or greater
nonhematologic toxicity than individuals of normal weight
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Figure 2. Kaplan-Meier plots of progression-free survival (A) and overall survival (B) by body mass index (BMI). Two-sided stratified log-rank test was used with stratifi-
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Table 2. Patient characteristics by baseline physical activity (n ¼ 492)
Physical activity MET hours per week
Characteristic

> 9 (n ¼ 154)

P

57 (28-86)

57 (33-83)

.29a
.48b

83 (24.6)
214 (63.3)
41 (12.1)

40 (26.0)
101 (65.6)
13 (8.4)

3 (0.9)
335 (99.1)

5 (3.2)
149 (96.8)

263 (77.8)
56 (16.6)
19 (5.6)

127 (82.5)
17 (11.0)
10 (6.5)

159 (47.0)
179 (53.0)

64 (41.6)
90 (58.4)

268 (79.3)
69 (20.5)
1

115 (74.7)
39 (25.3)
0

38 (11.2)
68 (20.1)
36 (10.7)
196 (58.0)

14 (9.1)
38 (24.7)
14 (9.1)
88 (57.1)

27 (8.6)
286 (91.4)
25

13 (9.4)
126 (90.6)
15

254 (75.1)
84 (24.9)

112 (72.7)
42 (27.3)

187 (57.2)
140 (42.8)
11

112 (75.7)
36 (24.3)
6

.05

.27b

.26b

.23b

.63b

.80b

.57b

<.001b

a

Two-sided Wilcoxon rank sum test or Kruskal-Wallis test. ECOG ¼ Eastern Cooperative Oncology Group; ER ¼ estrogen receptor; MET ¼ metabolic equivalents of task;

PR ¼ progesterone receptor.
Two-sided v2 test.

b

(P ¼ .05). There were no statistically significant differences in
rates of hematologic or nonhematologic toxicity by PA.
Given that chemotherapy-induced peripheral neuropathy is
the most prevalent nonhematologic toxicity associated with
taxane treatment, the relationship between BMI and PA and the
incidence of grade 2 or greater neurotoxicity was explored.
Among participants treated with ixabepilone, the incidence of
grade 2 or greater neurotoxicity differed with respect to PA, with
67.5% of individuals completing more than 9 MET hours per
week experiencing neuropathy vs 43.4% in individuals reporting
0-9 MET hours per week (P ¼ .009). There were no statistically
significant differences in rates of neurotoxicity by BMI.

Discussion
In the largest study to date evaluating the relationship between BMI
and recreational PA to cancer outcomes in individuals with MBC,
there was no statistically significant relationship between either BMI

or recreational PA and PFS or OS. Although OS was marginally longer
in participants who engaged in higher levels of PA, especially in
those with hormone receptor–positive cancers, these relationships
were not statistically significant. Notably, in this cohort of individuals initiating first-line chemotherapy for MBC, the prevalence of
obesity and inactivity were high, with 42.6% of participants
classified as obese and 47.6% engaging in less than an hour of
recreational moderate-intensity PA each week. Although the
majority of study participants experienced chemotherapy toxicity, BMI and PA were generally not associated with treatment
toxicity, with the exception of higher rates of toxicity in participants with obesity who were treated with ixabepilone and
higher rates of neurotoxicity in participants treated with ixabepilone who engaged in greater amounts of PA.
Our data regarding the lack of relationship between BMI and
PFS and OS are consistent with a pooled analysis looking at the relationship between BMI and cancer outcomes in 489 Italian
patients with MBC participating in 3 clinical trials of first-line
anthracycline and/or taxane-based chemotherapy (12). In that
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Median age (range), y
Age, No. (%), y
20-49
50-69
70 to 80
Sex, No. (%)
Male
Female
Race, No. (%)
White
Black
Other/unknown
Taxane as adjuvant therapy, No. (%)
Yes
No
Visceral metastases, No. (%)
Yes
No
Missing
Disease-free interval, No. (%)
0 (de novo)
<1 y
1 y < disease-free interval < 2 y
>2 y
Clinical stage, No. (%)
Not IV
IV
Missing
Tumor subtype, No. (%)
ER and/or PR positive
ER and PR negative
ECOG performance, No. (%)
0
1
Missing

0-9 (n ¼ 338)
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factors including treatment assignment, hormone receptor status, prior taxane, and use of bevacizumab. MET ¼ metabolic equivalents of task.

analysis, the median PFS was 10.9 months in normal weight individuals, 13.0 months in overweight individuals, and 12.2 months in
individuals with obesity (P ¼ .17). Median OS was 32.0 months in
normal weight individuals, 33.2 months in overweight individuals,
and 30.7 months in individuals with obesity (P ¼ .60).
Other reports have evaluated the relationship between BMI
and cancer outcomes in individuals with MBC with mixed
results (8–11). In patients initiating first-line HER2–directed
therapy for MBC, 2 studies did not demonstrate any relationship
between BMI and PFS (8,9), but 1 study did find a relationship
between obesity and higher risk of overall mortality (HR ¼ 1.29,
95% CI ¼ 1.09 to 1.52; P ¼ .003) in women treated with pertuzumab with or without ado-trastuzumab emtansine (8). Similarly,

in patients with MBC and brain metastases, 1 study of 84 individuals with newly diagnosed brain metastases treated with radiation demonstrated a statistically significant shorter OS in
patients with a BMI of 25 kg/m2 or more vs less than 25 kg/m2
(13.7 months vs 30.6 months; P < .001) (10), and a second study
of 228 individuals with MBC and brain metastases did not find a
statistically significant relationship between BMI and OS (10,11).
More work is needed to understand the relationship between
BMI and outcomes in individuals with advanced cancer in these
populations, but our work and the pooled Italian analyses suggest that there is unlikely to be a statistically significant relationship between BMI and outcomes in the broader population
of individuals with MBC.
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Figure 3. Kaplan-Meier plots of progression-free survival (A) and overall survival (B) by physical activity. Two-sided stratified log-rank test was used with stratification
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(b) and overall survival by physical activity for patients with hormone receptor–negative (c) and hormone receptor–positive disease (D). Two-sided stratified log-rank
tests were used with treatment assignment as the stratification factor. MET ¼ metabolic equivalents of task.

Table 3. Proportion of participants with grade 3 or higher toxicity by body mass index and physical activity
Body mass index
(n ¼ 792)
Treatment assignment and toxicity category

Normal

Overweight

Obese

Paclitaxel, No.
Hematologic, No. (%)
Nonhematologic, No. (%)
Nab-paclitaxel, No.
Hematologic, No. (%)
Nonhematologic, No. (%)
Ixabepilone, No.
Hematologic, No. (%)
Nonhematologic, No. (%)

74
19 (25.7)
45 (60.8)
71
32 (45.1)
49 (69.0)
64
8 (12.5)
33 (51.6)

79
19 (24.1)
49 (62.0)
93
52 (55.9)
63 (67.7)
76
6 (7.9)
51 (67.1)

129
26 (20.2)
79 (61.2)
104
62 (59.6)
76 (73.1)
102
14 (13.7)
71 (69.6)

Physical activity (MET hours per week)
(n ¼ 495)
P

.63
.99
.16
.70
.47
.05

0-9

>9

115
27 (23.5)
73 (63.5)
120
69 (57.5)
87 (72.5)
106
12 (11.3)
65 (61.3)

64
13 (20.3)
40 (62.5)
50
28 (56.0)
34 (68.0)
40
5 (12.5)
23 (57.5)

Pa

.63
.90
.86
.56
.84
.67

a

Two-sided v2 test. MET ¼ metabolic equivalents of task.

There is less information regarding PA patterns, and the relationship between PA and outcomes, in individuals with MBC.
Our study suggested that less than one-third of study

participants engaged in recommended levels of weekly recreational PA, and 47.6% engaged in little or no regular PA at study
entry. Notably, we found that individuals who reported more PA
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Figure 4. Kaplan-Meier plots of progression-free survival by physical activity for patients with hormone receptor–negative (a) and hormone receptor–positive disease
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